Cost-Effectiveness and Mortality Findings Presented at TCT 2026
Early transcatheter aortic valve replacement for asymptomatic severe aortic stenosis costs a mean $68,572 over five years compared to $85,044 for clinical surveillance, according to findings from the EARLY TAVR trial presented at TCT 2026. Neel Butala, MD, MBA, FACC, and trial investigators randomized 901 patients aged 65 and older to preemptive TAVR or clinical surveillance. Researchers project an eventual lifetime cost increase of roughly $4,500 paired with a gain of 0.3 quality-adjusted life years, yielding an incremental cost-effectiveness ratio of $14,698 per quality-adjusted life year gained.
Survival Risks Tied to Tricuspid Regurgitation Severity
Mortality risk climbs steadily as tricuspid regurgitation severity worsens, based on an analysis of 180,977 patients from the National Echocardiographic Database of Australia evaluated by Rebecca T. Hahn, MD, FACC, and colleagues. When researchers compared outcomes against mild tricuspid regurgitation, the adjusted hazard ratio for all-cause mortality started at 1.257 for moderate tricuspid regurgitation and reached 2.129 for torrential grades. Female patients demonstrated lower all-cause mortality alongside higher premature mortality, resulting in similar life years lost.
Outcomes from the TRIC-I-HF-DZHK24 Trial on Tricuspid Repair
Transcatheter tricuspid valve repair paired with optimal medical therapy outperformed optimal medical therapy alone in patients suffering from severe symptomatic tricuspid regurgitation at elevated risk for heart failure events. Jörg Hausleiter, MD, and study co-investigators analyzed 29,151 patient pairs in the TRIC-I-HF-DZHK24 trial. Their win ratio analysis revealed a score of 2.24 with a 95% confidence interval spanning 1.76 to 3.33 and a p-value below 0.0001, demonstrating reductions in both mortality and heart failure hospitalizations alongside quality-of-life gains measured via the KCCQ. The trial noted these benefits extended across patients with and without prior heart failure hospitalizations, as well as those with secondary organ dysfunction.
Questions Regarding Structural Heart Interventions
Why did EARLY TAVR researchers deem preemptive replacement cost-effective despite higher initial expenses?
Investigators point to short-term symptom avoidance, a lower risk of stroke, and a trend toward improved survival that generated small gains in quality-adjusted life years.
Which patient groups showed benefits from transcatheter tricuspid valve repair in the TRIC-I-HF-DZHK24 trial?
The superiority of tricuspid repair appeared in patients with and without prior heart failure hospitalizations, with and without secondary organ dysfunction and in patients with severe and massive tricuspid regurgitation.
How did researchers handle torrential tricuspid regurgitation during the trial?
Results for torrential tricuspid regurgitation were inconclusive due to small sample size.
Related reading